Pfizer Inc. (NYSE:PFE) Position Trimmed by S.A. Mason LLC

S.A. Mason LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 16.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 7,386 shares of the biopharmaceutical company’s stock after selling 1,453 shares during the period. S.A. Mason LLC’s holdings in Pfizer were worth $213,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PFE. State Street Corp raised its holdings in Pfizer by 1.9% during the 2nd quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock worth $10,534,558,000 after buying an additional 5,374,611 shares during the period. Moneta Group Investment Advisors LLC boosted its stake in Pfizer by 89,592.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. grew its position in Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Morgan Stanley raised its stake in Pfizer by 0.4% during the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after purchasing an additional 348,628 shares during the period. Finally, Norges Bank acquired a new stake in shares of Pfizer in the fourth quarter worth $3,150,472,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of several research analyst reports. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Barclays lowered their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a report on Thursday, December 14th. Finally, UBS Group cut their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a report on Thursday, December 14th. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Trading Up 0.7 %

Pfizer stock opened at $27.77 on Thursday. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market capitalization of $157.25 billion, a PE ratio of 77.14, a PEG ratio of 1.24 and a beta of 0.61. The business’s 50-day simple moving average is $27.47 and its 200-day simple moving average is $29.47.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the previous year, the business posted $1.14 EPS. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.